Kuhnil Pharmaceutical
CompanySouth Korea
Kuhnil Pharmaceutical develops 3 assets, the furthest approved (dexamethasone in burns). Mostly small molecule and peptide acting on inflammation, NF-κB signalling and apoptosis; based in South Korea.
- 3
- Assets
- Furthest
- Approved
- 26
- Trials
- 3
- Signals
Pipeline
3Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects
Approved, Small molecule, NF-κB signalling, Apoptosis, burns, Conjunctivitis, Allergic
Melatonin receptor agonist that regulates circadian rhythm and sleep-wake cycles.
Approved, Small molecule, Oxidative stress and ROS signalling, Inflammation, autism spectrum disorder, autistic disorder
GLP-1 receptor agonist stimulating glucose-dependent insulin secretion and lowering blood glucose.
Approved, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, cardiovascular disease, chronic kidney disease
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms10
- Trials32
- Signals8
- Similar companies6
Updated 8 Oct 2026 · 164 sources